FY2024 EPS Estimates for NeuroPace Lifted by Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of NeuroPace in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($1.03) for the year, up from their prior estimate of ($1.10). The consensus estimate for NeuroPace’s current full-year earnings is ($1.08) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.03) EPS.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same period last year, the business posted ($0.36) earnings per share. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a report on Wednesday, August 14th. Wells Fargo & Company decreased their target price on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, NeuroPace has an average rating of “Moderate Buy” and an average price target of $14.60.

NeuroPace Price Performance

Shares of NASDAQ NPCE opened at $8.98 on Friday. The firm has a market cap of $262.19 million, a P/E ratio of -8.98 and a beta of 1.79. The business’s 50 day moving average is $6.93 and its 200-day moving average is $7.48. The company has a current ratio of 5.59, a quick ratio of 5.47 and a debt-to-equity ratio of 6.03. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently modified their holdings of NPCE. Rhumbline Advisers acquired a new position in NeuroPace during the second quarter worth about $111,000. Financial Advocates Investment Management increased its position in NeuroPace by 50.0% during the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after purchasing an additional 5,000 shares in the last quarter. Barclays PLC increased its position in NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after purchasing an additional 16,007 shares in the last quarter. Hillsdale Investment Management Inc. bought a new position in NeuroPace in the 1st quarter valued at approximately $155,000. Finally, XTX Topco Ltd boosted its position in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after buying an additional 8,643 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other NeuroPace news, major shareholder Ltd. Kck sold 223,991 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares of the company’s stock, valued at approximately $28,726,105.25. This trade represents a 4.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 257,590 shares of company stock valued at $1,437,916 over the last quarter. 22.20% of the stock is owned by company insiders.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.